A synthetic analog of Thymosin Beta-4 that promotes systemic healing through actin regulation and angiogenesis.
Prohibited in competition. This compound is on the WADA Prohibited List (class [S0 / S2.3 / S2]), banned at all times, both in and out of competition. Athletes subject to WADA or USADA testing should not use it.
TB-500 is a synthetic peptide corresponding to the actin-binding domain (amino acids 17–23) of Thymosin Beta-4 (TB4), a naturally occurring 43-amino acid peptide found in virtually all human cells. Thymosin Beta-4 is one of the most abundant intracellular peptides in mammals and is the primary G-actin sequestering peptide in cells. Whether the fragment reproduces the activity of full-length Thymosin Beta-4 has not been established. FDA has identified no human exposure data for the fragment, and evidence generated with full-length Tβ4 does not transfer to it. Unlike BPC-157, which has primarily local healing effects at the injection site, TB-500 provides systemic healing effects throughout the body, making it particularly valuable for widespread injuries, systemic inflammation, or tissues that are difficult to inject directly (such as tendons deep within joints or cardiac tissue). TB-500 has demonstrated remarkable healing effects in animal models of cardiac injury, tendon damage, corneal wounds, and neurological injury. It is commonly combined with BPC-157 for comprehensive tissue repair.
4963.5 Da
2–5 mg
“A synthetic analog of Thymosin Beta-4 that promotes systemic healing through actin regulation and angiogenesis.”
TB-500’s primary mechanism involves sequestration of G-actin (monomeric actin) through its LKKTET actin-binding motif. By regulating the balance between G-actin and F-actin (filamentous actin), TB-500 controls cell migration, proliferation, and differentiation — all critical processes in tissue repair. Specifically, it promotes the migration of keratinocytes, endothelial cells, and fibroblasts into wound sites, accelerating wound closure. TB-500 also upregulates VEGF (vascular endothelial growth factor) and its receptor VEGFR2, promoting angiogenesis (new blood vessel formation) that is essential for tissue repair and regeneration. It reduces the expression of pro-inflammatory cytokines (IL-1β, TNF-α) and promotes the transition from the inflammatory to the proliferative phase of wound healing. In cardiac tissue, TB-500 has demonstrated the ability to activate cardiac progenitor cells and promote cardiomyocyte regeneration after ischemic injury — a property unique among peptides studied for cardiac repair.
When sourcing TB-500 for research purposes, the following quality benchmarks should be verified before use.
>98% (verified by HPLC)
Must be provided by supplier
<0.1 EU/mg (prevents bacterial contamination)
Manufactured in cGMP-certified facility
Independent lab verification preferred
TB-500 is prohibited by WADA under class S2.3 (growth factors and growth-factor modulators), at all times, both in and out of competition.
Regulatory status
FDA placed TB-500 in Category 2 (significant safety risks) in September 2023. It is not FDA-approved and is not a lawful dietary ingredient. FDA has identified no human exposure data for the fragment.
Unresolved safety questions
TB-500 upregulates VEGF and VEGFR2. That pro-angiogenic mechanism carries the same unresolved tumour-promotion questions as other angiogenic agents, and has not been studied for that risk in humans.
Lyophilized: refrigerate. Reconstituted: refrigerate and use within 30 days.
The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.
Multiple animal studies and/or early human trials. Reasonable confidence in mechanism, but human data is limited.
Peptides commonly used alongside TB-500 for synergistic effects.
A synthetic pentadecapeptide derived from gastric juice with extraordinary tissue healing properties across multiple organ systems.
A short-acting GHRH analog that produces physiological GH pulses when combined with a GHRP like Ipamorelin.
The most selective GHRP available, stimulating GH release with minimal cortisol or prolactin elevation.
Category
Status
Dose
Frequency
Cycle
Peptides
Protocols
Other Pages
Contact Us Today!
© 2026 Best Health IQ. All rights reserved.
FDA Disclaimer: The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many compounds described on this site are not approved by the FDA for human therapeutic use. Some are available only as compounded preparations or as materials sold for laboratory use, and several are on FDA's Category 2 list for significant safety risks. Nothing on this site constitutes medical advice or a recommendation to use any compound described.
